Coronary Artery Dysfunction After Stent Implantation and Effect of Aggressive Lipid-lowering Therapy by Statins - Role of Rho-kinase -

Coronary Artery Dysfunction After Stent Implantation and Effect of Aggressive Lipid-lowering Therapy by Statins - Role of Rho-kinase - - Coronary Dysfunction After Stenting and Aggressive Lipid-lowering - Role of Rho-kinase - (CONTRACTION study)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000888

Enrollment

200

Registered

2007-11-15

Start date

2007-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic heart disease

Interventions

Control therapy: Slow-release nifedipine (Adalat CR) 20/40mg/day or slow-release diltiazem (Herbesser R) 200mg/day if hypotension is a concern. Lipid-lowering therapy to achieve LDL-Chol&lt

100mg/dl with statins if needed. Experimental therapy: Slow-release nifedipine (Adalat CR) 20/40mg/day or slow-release diltiazem (Herbesser R) 200mg/day if hypotension is a concern. Aggressive lip

70mg/dl with pitavastatin (Livalo) 2-4mg/day.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patient of coronary heart disease with prior coronary stenting 2. Patient is planned to undergo follow-up coronary angiography 3. LDL-Chol>70mg/dl 4. Written informed consent for this study

Exclusion criteria

Exclusion criteria: 1. Patient with unstable angina or acute myocardial infarction 2. History of angiographycally-proven vasospastic angina 3. Contraindication for statins or calcium channel blockers 4. Familial hypercholesterolemia, liver cirrhosis or renal failure on chronic dialysis 5. Contraindication for intracoronary acetylcholine during coronary angiography

Design outcomes

Primary

Measure	Time frame
Coronary vasospasm after 3-month trial therapy	—

Secondary

Measure	Time frame
1) Cardiovascular events (cardiac death, myocardial infarction, revascularization by PCI or CABG) 2) Severity of angina by Canadian Cardiovascular Society (CCS) classification 3) Biomarkers in peripheral and coronary sinus blood 4) Coronary stenosis and plaque phenotype by angiography or intravascular ultrasound (IVUS) 5) Stent re-endothelialization by angioscopy or optical coherence tomography (OCT)	—

Measure

Time frame

1) Cardiovascular events (cardiac death, myocardial infarction, revascularization by PCI or CABG) 2) Severity of angina by Canadian Cardiovascular Society (CCS) classification 3) Biomarkers in peripheral and coronary sinus blood 4) Coronary stenosis and plaque phenotype by angiography or intravascular ultrasound (IVUS) 5) Stent re-endothelialization by angioscopy or optical coherence tomography (OCT)

—

Countries

Japan

Contacts

Public ContactTetsuya Matoba

Kyushu University Graduate School of Medical Sciences Department of Cardiovascular Medicine

matoba@cardiol.med.kyushu-u.ac.jp092-642-5360

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026